In the next several months, the president and members of Congress will decide whether to continue the funding and authorities associated with Project BioShield, which seeks to expand the U.S. stockpile of medical countermeasures for potential chemical, biological, radiological and nuclear attacks. In Renewing the Project BioShield Act: What Has It Bought and Wrought?, Dr. Robert Kadlec, a consultant with RPK Consulting, writes that Project BioShield has achieved its strategic objectives and merits continued support and funding. He argues that the president and Congress should affirm its value as a critical insurance policy against the risk of these types of attacks.
If You Want Peace, Prepare for Nuclear War
By Elbridge Colby
What should be done with report on military sexual harassment and assault?
By Kayla M. Williams
Why ROTC is the overlooked tool to challenge the civil-military divide
By Emma Moore
Leveraging ROTC to Span the Civil-Military Gap
By Emma Moore & Andrew Swick